-
Je něco špatně v tomto záznamu ?
Role of Hb to RDW ratio in metastatic renal cell carcinoma patients treated with first-line immunotherapy combinations
M. Corianò, A. Lazzarin, M. Maffezzoli, M. Santoni, G. Mazzaschi, S. Rodella, N. Simoni, E. Lai, M. Maruzzo, U. Basso, D. Bimbatti, R. Iacovelli, A. Anghelone, O. Fiala, SE. Rebuzzi, G. Fornarini, C. Lolli, F. Massari, M. Rosellini, V. Mollica,...
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu časopisecké články, multicentrická studie, pozorovací studie
- MeSH
- dospělí MeSH
- erytrocytární znaky MeSH
- hemoglobiny * analýza metabolismus MeSH
- imunoterapie * metody MeSH
- inhibitory kontrolních bodů terapeutické užití MeSH
- karcinom z renálních buněk * farmakoterapie terapie krev MeSH
- lidé středního věku MeSH
- lidé MeSH
- nádory ledvin * farmakoterapie terapie krev patologie mortalita imunologie MeSH
- prognóza MeSH
- retrospektivní studie MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- multicentrická studie MeSH
- pozorovací studie MeSH
BACKGROUND: The present study aimed to investigate the prognostic and predictive roles of Hb/RDW ratio in patients with mRCC treated with first-line immunotherapy combinations (TKI plus ICI or ICI plus ICI). MATERIALS AND METHODS: We performed a sub-analysis of a multicenter retrospective observational study (ARON-1 project) involving patients with mRCC treated with first-line immunotherapy combinations. RESULTS: Three hundred and twenty-nine patients were enrolled, 244 males and 85 females. Median age was 65.5 years. The prognostic impact of the Hb/RDW ratio on PFS and OS was observed in the whole population examined. Hb/RDW ratio had a correlation with neutrophil-to-lymphocyte ratio (NLR), a blood inflammatory parameter. CONCLUSION: Hb/RDW ratio is a new inflammatory prognostic factor, easy to use in daily clinical practice.
Biomedical Centre Faculty of Medicine in Pilsen Charles University Pilsen Czech Republic
Department of Diagnostic and Public Health Section of Pathology University of Verona Verona Italy
Department of Internal Medicine and Medical Specialties University of Genova Genova Italy
Department of Medicine and Surgery Section of Radiology University of Parma Parma Italy
Department of Medicine and Surgery University of Parma Parma Italy
Department of Oncology Portsmouth Hospitals University NHS Trust Portsmouth UK
Medical Oncology Fondazione Policlinico Universitario Agostino Gemelli IRCCS Roma Italy
Medical Oncology IRCCS Azienda Ospedaliero Universitaria di Bologna Bologna Italy
Medical Oncology Ospedale Santa Corona Pietra Ligure Italy
Medical Oncology Unit Ospedale San Paolo institution Savona Italy
Medical Oncology Unit University Hospital of Parma Parma Italy
Medical Oncology Unit University of Brescia Brescia Italy
Oncology Unit Department of Oncology Istituto Oncologico Veneto IOV IRCCS Padua Italy
Oncology Unit Macerata Hospital Macerata Italy
Pathology Unit University Hospital of Parma Parma Italy
Radiotherapy Unit University Hospital of Parma Parma Italy
Section of biostatistics Department of Health Sciences University of Genova Genova Italy
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc25010391
- 003
- CZ-PrNML
- 005
- 20250429135204.0
- 007
- ta
- 008
- 250415s2025 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1080/1750743X.2025.2452145 $2 doi
- 035 __
- $a (PubMed)39829377
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Corianò, Matilde $u Department of Medicine and Surgery, University of Parma, Parma, Italy $u Medical Oncology Unit, University Hospital of Parma, Parma, Italy
- 245 10
- $a Role of Hb to RDW ratio in metastatic renal cell carcinoma patients treated with first-line immunotherapy combinations / $c M. Corianò, A. Lazzarin, M. Maffezzoli, M. Santoni, G. Mazzaschi, S. Rodella, N. Simoni, E. Lai, M. Maruzzo, U. Basso, D. Bimbatti, R. Iacovelli, A. Anghelone, O. Fiala, SE. Rebuzzi, G. Fornarini, C. Lolli, F. Massari, M. Rosellini, V. Mollica, C. Nasso, A. Acunzo, EM. Silini, F. Quaini, M. De Filippo, M. Brunelli, GL. Banna, P. Rescigno, A. Signori, S. Buti
- 520 9_
- $a BACKGROUND: The present study aimed to investigate the prognostic and predictive roles of Hb/RDW ratio in patients with mRCC treated with first-line immunotherapy combinations (TKI plus ICI or ICI plus ICI). MATERIALS AND METHODS: We performed a sub-analysis of a multicenter retrospective observational study (ARON-1 project) involving patients with mRCC treated with first-line immunotherapy combinations. RESULTS: Three hundred and twenty-nine patients were enrolled, 244 males and 85 females. Median age was 65.5 years. The prognostic impact of the Hb/RDW ratio on PFS and OS was observed in the whole population examined. Hb/RDW ratio had a correlation with neutrophil-to-lymphocyte ratio (NLR), a blood inflammatory parameter. CONCLUSION: Hb/RDW ratio is a new inflammatory prognostic factor, easy to use in daily clinical practice.
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a retrospektivní studie $7 D012189
- 650 _2
- $a senioři $7 D000368
- 650 12
- $a karcinom z renálních buněk $x farmakoterapie $x terapie $x krev $7 D002292
- 650 12
- $a imunoterapie $x metody $7 D007167
- 650 _2
- $a lidé středního věku $7 D008875
- 650 12
- $a nádory ledvin $x farmakoterapie $x terapie $x krev $x patologie $x mortalita $x imunologie $7 D007680
- 650 12
- $a hemoglobiny $x analýza $x metabolismus $7 D006454
- 650 _2
- $a prognóza $7 D011379
- 650 _2
- $a erytrocytární znaky $7 D004909
- 650 _2
- $a inhibitory kontrolních bodů $x terapeutické užití $7 D000082082
- 650 _2
- $a senioři nad 80 let $7 D000369
- 650 _2
- $a dospělí $7 D000328
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a multicentrická studie $7 D016448
- 655 _2
- $a pozorovací studie $7 D064888
- 700 1_
- $a Lazzarin, Alessandro $u Department of Medicine and Surgery, University of Parma, Parma, Italy $u Medical Oncology Unit, University Hospital of Parma, Parma, Italy
- 700 1_
- $a Maffezzoli, Michele $u Department of Medicine and Surgery, University of Parma, Parma, Italy $u Medical Oncology Unit, University Hospital of Parma, Parma, Italy $1 https://orcid.org/0000000178778988
- 700 1_
- $a Santoni, Matteo $u Oncology Unit, Macerata Hospital, Macerata, Italy
- 700 1_
- $a Mazzaschi, Giulia $u Department of Medicine and Surgery, University of Parma, Parma, Italy $u Medical Oncology Unit, University Hospital of Parma, Parma, Italy
- 700 1_
- $a Rodella, Sara $u Medical Oncology Unit, University of Brescia, Brescia, Italy
- 700 1_
- $a Simoni, Nicola $u Radiotherapy Unit, University Hospital of Parma, Parma, Italy
- 700 1_
- $a Lai, Eleonora $u Oncology Unit, Department of Oncology, Istituto Oncologico Veneto IOV IRCCS, Padua, Italy
- 700 1_
- $a Maruzzo, Marco $u Oncology Unit, Department of Oncology, Istituto Oncologico Veneto IOV IRCCS, Padua, Italy
- 700 1_
- $a Basso, Umberto $u Oncology Unit, Department of Oncology, Istituto Oncologico Veneto IOV IRCCS, Padua, Italy
- 700 1_
- $a Bimbatti, Davide $u Oncology Unit, Department of Oncology, Istituto Oncologico Veneto IOV IRCCS, Padua, Italy
- 700 1_
- $a Iacovelli, Roberto $u Medical Oncology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma, Italy
- 700 1_
- $a Anghelone, Annunziato $u Medical Oncology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma, Italy
- 700 1_
- $a Fiala, Ondřej $u Department of Oncology and Radiotherapeutics, Faculty of Medicine and University Hospital in Pilsen, Charles University, Pilsen, Czech Republic $u Biomedical Centre, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic
- 700 1_
- $a Rebuzzi, Sara Elena $u Medical Oncology Unit, Ospedale San Paolo institution, Savona, Italy $u Department of Internal Medicine and Medical Specialties (Di.M.I.), University of Genova, Genova, Italy
- 700 1_
- $a Fornarini, Giuseppe $u Department of Oncology and Hematology, Medical Oncology Unit 1, IRCCS Ospedale Policlinico San Martino, Genova, Italy
- 700 1_
- $a Lolli, Cristian $u Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy
- 700 1_
- $a Massari, Francesco $u Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy
- 700 1_
- $a Rosellini, Matteo $u Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy
- 700 1_
- $a Mollica, Veronica $u Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy
- 700 1_
- $a Nasso, Cecilia $u Medical Oncology, Ospedale Santa Corona, Pietra Ligure, Italy
- 700 1_
- $a Acunzo, Alessandro $u Department of Medicine and Surgery, University of Parma, Parma, Italy $u Medical Oncology Unit, University Hospital of Parma, Parma, Italy
- 700 1_
- $a Silini, Enrico Maria $u Department of Medicine and Surgery, University of Parma, Parma, Italy $u Pathology Unit, University Hospital of Parma, Parma, Italy
- 700 1_
- $a Quaini, Federico $u Department of Medicine and Surgery, University of Parma, Parma, Italy
- 700 1_
- $a De Filippo, Massimo $u Department of Medicine and Surgery, Section of Radiology, University of Parma, Parma, Italy
- 700 1_
- $a Brunelli, Matteo $u Department of Diagnostic and Public Health, Section of Pathology, University of Verona, Verona, Italy
- 700 1_
- $a Banna, Giuseppe L $u Department of Oncology, Portsmouth Hospitals University NHS Trust, Portsmouth, UK $u Faculty of Science and Health, School of Pharmacy and Biomedical Sciences, University of Portsmouth, Portsmouth, UK
- 700 1_
- $a Rescigno, Pasquale $u Translational and Clinical Research Institute, Centre for Cancer, Newcastle University, Newcastle upon Tyne, UK
- 700 1_
- $a Signori, Alessio $u Section of biostatistics, Department of Health Sciences (DISSAL), University of Genova, Genova, Italy
- 700 1_
- $a Buti, Sebastiano $u Department of Medicine and Surgery, University of Parma, Parma, Italy $u Medical Oncology Unit, University Hospital of Parma, Parma, Italy $1 https://orcid.org/0000000308760226
- 773 0_
- $w MED00175821 $t Immunotherapy $x 1750-7448 $g Roč. 17, č. 1 (2025), s. 25-35
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/39829377 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20250415 $b ABA008
- 991 __
- $a 20250429135159 $b ABA008
- 999 __
- $a ok $b bmc $g 2311632 $s 1247472
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2025 $b 17 $c 1 $d 25-35 $e 20250120 $i 1750-7448 $m Immunotherapy $n Immunotherapy $x MED00175821
- LZP __
- $a Pubmed-20250415
